Physician profile
Libby Rhee
NPI 1265738884
$430,044.45
in general payments reported to CMS, 2019-2025
38 companies · $58K in 2025
The $58K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $35K · 2021: $34K · 2022: $48K · 2023: $81K · 2024: $86K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $179K · Consulting Fee: $18K · Travel and Lodging: $16K · Food and Beverage: $11K · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $179,275.00 |
| Consulting Fee | $18,000.00 |
| Travel and Lodging | $16,023.34 |
| Food and Beverage | $11,346.57 |
| Education | $378.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396,536.83 | 2019-2025 | |
| Incyte Corporation | $14,724.52 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $3,259.87 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $2,877.81 | 2019-2025 | Libtayo |
| Galderma Laboratories, L.P. | $1,722.14 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Genzyme Corporation | $1,331.09 | 2019-2025 | |
| Lilly USA, LLC | $1,056.76 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $868.94 | 2020-2025 | Tremfya |
| Journey Medical Corporation | $668.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $599.35 | 2022-2025 | Sotyktu |
| Allergan, INC. | $572.12 | 2019-2022 | |
| Pfizer INC. | $568.25 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $554.22 | 2019-2025 | |
| Amgen INC. | $500.10 | 2020-2025 | Otezla |
| Promius Pharma LLC | $500.00 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $499.64 | 2021-2023 | Xeomin |
| Sun Pharmaceutical Industries INC. | $496.34 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $495.43 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $292.67 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $274.45 | 2019-2023 | Duobrii, Siliq |
| Almirall LLC | $255.80 | 2020-2025 | Seysara, Klisyri |
| Biofrontera INC. | $229.76 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sanofi-Aventis U.S. LLC | $213.65 | 2019-2025 | |
| Epi Health, LLC | $199.57 | 2020-2022 | |
| Ucb, INC. | $194.19 | 2024-2025 | Bimzelx |
| Celgene Corporation | $115.72 | 2019 | |
| Mayne Pharma Commercial LLC | $76.58 | 2019-2025 | |
| Botanix Sb INC | $72.43 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $68.92 | 2020 | |
| Cipher Pharmaceuticals US LLC | $62.88 | 2025 | Natroba, Spinosad |
| Mission Pharmacal Company | $26.36 | 2019-2021 | |
| Lnhc, INC | $24.04 | 2025 | Zelsuvmi |
| Prugen, INC. Pharmaceuticals | $21.15 | 2019 | |
| Kyowa Kirin, INC. | $21.00 | 2024 | Poteligeo |
| Medimetriks Pharmaceuticals, INC. | $20.39 | 2019 | |
| Fidia Pharma USA INC. | $15.19 | 2024 | |
| Encore Dermatology INC. | $15.09 | 2020 | |
| Solta Medical, A Division of Bausch Health US, LLC | $13.10 | 2024 | Clear+Brilliant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libby Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.